Pulmonary Embolism Subacute Massive
10
2
2
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
10.0%
1 terminated out of 10 trials
66.7%
-19.9% vs benchmark
10%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (10)
Pulmonary Embolism Registry From Emergency to Long-Term Follow-Up and Surveillance
Multimodal Physiologic State Intelligence Study
Effect of iNO in Patients With Submassive and Massive PE
Non-Invasive Measurement of Cardiac Output and Stroke Volume in PE
Effect of Thrombolysis on 30-day Mortality in Intermediate High Risk Pulmonary Patients With Low Bleeding Risk
Cohort Study on Treatment Comes of Catheter-based Therapy in Patients With Acute Pulmonary Embolism in Hong Kong
Artificial Intelligence to StrategiCally Enhance Pulmonary Embolism Response Team Activation
Safe Delivery of Thrombolytic Treatment for Pulmonary Embolism Using ClotPro® Viscoelastic Tests
Catheter Directed Therapy in Intermediate Risk Pulmonary Embolism Patients
Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism